GlaxoSmithKline PLC (NYSE:GSK) Stake Maintained by Rothschild Investment Corp IL

Rothschild Investment Corp IL held its stake in GlaxoSmithKline PLC (NYSE:GSK) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 28,586 shares of the pharmaceutical company’s stock at the end of the second quarter. Rothschild Investment Corp IL’s holdings in GlaxoSmithKline PLC were worth $1,233,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. FMR LLC boosted its stake in GlaxoSmithKline PLC by 11.7% in the first quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock worth $996,452,000 after buying an additional 2,482,009 shares in the last quarter. Fisher Asset Management LLC boosted its stake in GlaxoSmithKline PLC by 4.7% in the second quarter. Fisher Asset Management LLC now owns 12,534,385 shares of the pharmaceutical company’s stock worth $540,483,000 after buying an additional 564,519 shares in the last quarter. Bank of America Corp DE boosted its stake in GlaxoSmithKline PLC by 15.8% in the first quarter. Bank of America Corp DE now owns 6,849,632 shares of the pharmaceutical company’s stock worth $288,780,000 after buying an additional 934,928 shares in the last quarter. Renaissance Technologies LLC boosted its stake in GlaxoSmithKline PLC by 42.7% in the first quarter. Renaissance Technologies LLC now owns 4,402,100 shares of the pharmaceutical company’s stock worth $185,593,000 after buying an additional 1,316,600 shares in the last quarter. Finally, Brandes Investment Partners LP boosted its stake in GlaxoSmithKline PLC by 6.8% in the first quarter. Brandes Investment Partners LP now owns 3,363,788 shares of the pharmaceutical company’s stock worth $141,817,000 after buying an additional 214,167 shares in the last quarter. Institutional investors and hedge funds own 8.96% of the company’s stock.

GlaxoSmithKline PLC (NYSE GSK) traded down 0.28% on Friday, reaching $38.79. The company’s stock had a trading volume of 2,329,225 shares. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.59. The company has a market capitalization of $94.80 billion, a price-to-earnings ratio of 37.51 and a beta of 1.03. The stock has a 50 day moving average price of $41.84 and a 200-day moving average price of $41.84.

GlaxoSmithKline PLC (NYSE:GSK) last released its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. The firm had revenue of $9.36 billion during the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Equities analysts predict that GlaxoSmithKline PLC will post $2.85 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Stockholders of record on Friday, August 11th will be given a dividend of $0.491 per share. The ex-dividend date of this dividend is Wednesday, August 9th. This represents a $1.96 dividend on an annualized basis and a dividend yield of 5.06%. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. GlaxoSmithKline PLC’s dividend payout ratio is currently 197.00%.

WARNING: This news story was originally published by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another site, it was illegally copied and reposted in violation of US & international copyright and trademark law. The correct version of this news story can be accessed at https://www.thestockobserver.com/2017/08/12/glaxosmithkline-plc-nysegsk-stake-maintained-by-rothschild-investment-corp-il-updated-updated.html.

A number of equities research analysts have commented on GSK shares. Zacks Investment Research cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, July 21st. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $46.00.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply